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Objective: To analyze quality of life and demographic and clinical variables associated to its
impairment in a large Brazilian cohort of patients with spondyloarthritis (SpA).
Methods: A common protocol of investigation was applied to 1465 Brazilian patients clas-
siﬁed as SpA according to the European Spondyloarthropaties Study Group (ESSG) criteria,
attended at 29 reference centers for Rheumatology in Brazil. Clinical and demographic vari-
ables  were recorded. Quality of life was analyzed through the Ankylosing Spondylitis Quality
of  Life (ASQoL) questionnaire.
Results: The mean ASQoL score was 7.74 (+5.39). When analyzing the speciﬁc diseases in
the  SpA group, the ASQoL scores did not present statistical signiﬁcance. Demographic
data  showed worse scores of ASQoL associated with female gender (p = 0.014) and African-
Brazilian ethnicity (p < 0.001). The analysis of the clinical symptoms showed that buttock
pain (p = 0.032), cervical pain (p < 0.001) and hip pain (p = 0.001) were statistically associ-
ated  with worse scores of ASQoL. Continuous use of nonsteroidal anti-inﬂammatory drugs
(p  < 0.001) and biologic agents (p = 0.044) were associated with higher scores of ASQoL, while
the  other medications did not interfere with the ASQoL scores.
Conclusion: In this large series of patients with SpA, female gender and African-Brazilian
ethnicity, as well as predominant axial symptoms, were associated with impaired quality
of  life.
© 2015 Elsevier Editora Ltda. All rights reserved.
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Objetivo: Analisar a qualidade de vida e as variáveis demográﬁcas e clínicas associadas à
diminuic¸ão  da capacidade em uma grande coorte brasileira de pacientes com espondiloar-
trite  (EspA).
Métodos: Foi aplicado um protocolo de pesquisa único a 1.465 pacientes brasileiros classiﬁ-
cados  como tendo EspA de acordo com os critérios do European Spondyloarthropaties Study
Group (ESSG), atendidos em 29 centros de referência em Reumatologia do Brasil. Foram reg-
istradas as variáveis clínicas e demográﬁcas. A qualidade de vida foi analisada por meio do
questionário Ankylosing Spondylitis Quality of Life (ASQoL).
Resultados: A pontuac¸ão média do ASQoL foi de 7,74 (+5,39). Ao analisar doenc¸as especíﬁcas
no  grupo de EspA, as pontuac¸ões do ASQoL não apresentaram diferenc¸a estatisticamente
signiﬁcativa. Os dados demográﬁcos mostraram piores escores de ASQoL associados ao
gênero feminino (p = 0,014) e etnia afro-brasileira (p < 0,001). Quanto aos sintomas clínicos,
a  dor na região glútea (p = 0,032), a dor cervical (p < 0,001) e a dor no quadril (p = 0,001), bem
como  a presenc¸a de articulac¸ões periféricas inﬂamadas (p = 0,022), estiveram estatistica-mente associadas a piores escores no ASQoL. O uso contínuo de fármacos anti-inﬂamatórios
não  esteroides (p < 0,001) e agentes biológicos (p = 0,044) estiveram associados a escores mais
elevados de ASQoL, enquanto outros medicamentos não interferiram nos escores do ASQoL.
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Conclusão: Neste grande série de pacientes com EspA, o sexo feminino e a etnia afro-
brasileira, bem como alguns sintomas clínicos axiais e periféricos, estiveram associados
a  uma qualidade de vida reduzida.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
The spondyloarthritides (SpA) comprise a group of interre-
lated chronic inﬂammatory diseases, i.e. ankylosing spondyli-
tis (AS), psoriatic arthritis (PsA), SpA associated with
inﬂammatory bowel diseases (IBD), reactive arthritis (ReA),
juvenile onset SpA, and undifferentiated SpA. These diseases
share several clinical features such as inﬂammation of the
axial joints, asymmetric oligoarthritis (especially of the lower
limbs), and enthesitis. AS is a chronic inﬂammatory disease
that affects predominantly the spine and usually starts in the
young adult age, contributing to signiﬁcant physical disabil-
ity and decreased quality of life (QoL) in a signiﬁcant number
of patients.1 With the advent of new and effective agents for
the treatment of AS in the last decade, it became necessary to
develop methods that could reﬂect the real improvement in
the QoL of these patients.
In general, QoL can be measured by two groups of
instruments: generic instruments, applicable to patients with
various conditions, and disease speciﬁc instruments for use
in speciﬁc diseases.1 The generic instrument most commonly
used to be evaluate QoL in patients with SpA is the Medical
Outcome Short-Form 36 Health Survey (SF-36),2 that measures
health-related QoL through 8 domains (“physical functioning”,
“physical role”, “body pain”, “general health”, “vitality”, “social
functioning”, “emotional role” and “mental health”). In 2003,
the Ankylosing Spondylitis Quality of Life (ASQoL),3 a speciﬁc
instrument to analyze QoL in AS patients, was proposed; it
comprises 18 questions, and the poor QoL is associated with
the higher scores. ASQoL was developed in collaboration with
AS patients, is feasible and sensitive to change over time.3
ASQoL has been validated in many  countries.4–6 And as we do
not have speciﬁc questionnaires related to QoL in other dis-
eases in the SpA group, ASQoL can be used for the evaluation
of these SpA patients.
The objective of this study is to analyze the importance
of demographic and clinical variables in the QoL in a large
Brazilian cohort of patients with spondyloarthritis (SpA).
Methods
This is a prospective, observational, and multicentric cohort of
1465 consecutive patients with SpA recruited from 29 referral
centers participating in the Brazilian Registry of Spondy-
loarthritis (RBE – Registro Brasileiro de Espondiloartrites). All
patients, from all the 5 major geographic areas in Brazil,
were classiﬁed according to the European Spondylarthropathy
Study Group criteria,7 with data collected from June 2006 to
December 2009. The RBE is part of the RESPONDIA group com-
prising 9 Latin American countries (Argentina, Brazil, CostaRica, Chile, Ecuador, México, Peru, Uruguay, and Venezuela)
and the 2 Iberian Peninsula countries (Spain and Portugal).
A common protocol of investigation was applied to 1465
SpA patients. The diagnosis of AS was considered if the
patients fulﬁlled the New York modiﬁed criteria,8 and as pso-
riatic arthritis (PsA) in case they fulﬁlled the Moll and Wright
criteria9; reactive arthritis (ReA) was considered when asym-
metric inﬂammatory oligoarthritis of lower limbs was present,
associated with enthesopathy and/or inﬂammatory low back
pain following enteric or urogenital infections10; and entero-
pathic arthritis when the patient presented inﬂammatory
axial and/or peripheral joint involvement associated with con-
ﬁrmed inﬂammatory bowel disease (IBD; Crohn’s disease or
ulcerative colitis).
Demographic and clinical data were collected, including
time of disease duration, spinal pain, peripheral joint pain or
swelling, tender and swollen joint count, visual analog scale
for pain according to the patient (VAS for pain) and disease
activity according to patient and physician (patient and physi-
cian VAS for disease activity). Peripheral articular involvement
was assessed by the 66 tender/swollen joint count. Other
clinical variables as dactylitis, uveitis, HLA-B27 were also eval-
uated, as well as drug use.
Quality of life was evaluated using the ASQoL
questionnaire,3 that comprises 18 questions, each with a
dichotomous “yes/no” response, scored “1” and “0”, respec-
tively. Total score ranges from 0 to 18, with the higher scores
indicating poor quality of life. ASQoL had previously been
translated, cross-translated, validated, and culturally adapted
to the Brazilian Portuguese language.11
Statistical  analysis
Categorical variables were compared by 2 and Fisher’s exact
test, and continuous variables were compared by ANOVA
test. A value of p < 0.05 was considered signiﬁcant, and
0.05 > p > 0.10 was considered a statistical trend.
Results
A total of 1465 patients were evaluated, comprising 1059 men
and 406 women. AS was the most frequent disease in the group
(67.6%), followed by PsA (18.8%), USpA (6.8%), ReA (3.4%), and
enteropathic arthritis (3.4%). The mean score of ASQoL was
7.74 ± 5.39. There was no statistical signiﬁcance comparing the
ASQoL mean scores among the different diseases in the SpA
group, as shown in Table 1.The ASQoL mean scores were higher in the female gender
(p = 0.014), African-Brazilian ethnicity (p < 0.001) and in those
who practiced no exercises (p < 0.001). HLA-B27 and family his-
tory did not inﬂuenced the ASQoL scores (Table 2).
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Table 1 – ASQoL scores, according to the SpA.
N (%) ASQoL score p
Mean SD
AS 67.6 7.93 5.40
0.205
PsA 18.8 7.29 5.38
USpA 6.8 7.86 5.14
ReA 3.4 7.48 5.38
Arthritis – IBD 3.4 6.91 5.13
TOTAL 100 7.74 5.39
ASQoL, Ankylosing Spondylitis Quality of Life; AS, ankylos-
ing spondylitis; IBD, inﬂammatory bowel disease; PsA, pso-
riatic arthritis; ReA, reactive arthritis; USpA, undifferentiated
spondyloarthritis.
Table 2 – ASQoL scores, according to demographic
variables.
N (%) ASQoL score p
Mean SD
Gender
Male 72.3 7.53 5.40 0.014
Female 27.7 8.29 5.34
Race
Caucasian 67.4 7.10 5.40 <0.001
African-Brazilian 32.6 8.56 5.33
Exercise
Yes 40.8 6.90 5.29 <0.001
No 59.2 8.36 5.37
HLA-B27a
Positive 69.0 7.47 5.56 0.504
Negative 31.0 7.77 5.39
Family history
Yes 18.0 7.80 5.28 0.829
No 82.0 7.73 5.42
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Table 3 – ASQoL scores, according to clinical variables.
N (%) ASQoL score p
Mean SD
Low back pain
Yes 67.6 7.88 5.46 0.158
No 22.4 7.46 5.24
Buttock pain
Yes 33.1 8.18 5.66 0.032
No 66.9 7.52 5.24
Cervical pain
Yes 30.8 8.64 5.43 <0.001
No 69.2 7.34 5.33
Hip pain
Yes 25.1 8.56 5.49 0.001
No 31.0 7.46 5.33
Arthritis lower limbs
Yes 48.9 7.97 5.40 0.105
No 51.1 7.52 5.37
Arthritis upper limbs
Yes 22.1 8.00 5.39 0.327
No 77.9 7.67 5.39
Enthesitis
Yes 27.1 7.73 5.50 0.950
No 72.9 7.75 5.36
Dactilitis
Yes 9.1 7.29 5.58 0.331
No 90.9 7.79 5.37
Uveitis
Yes 19.1 7.70 5.38 0.888
No 80.9 7.75 5.40
Psoriasis
Yes 17.8 7.36 5.36 0.215
No 82.2 7.82 5.40
IBD
Yes 4.7 6.70 5.54 0.151
No 95.3 7.79 5.38
Urethritis
Yes 4.4 8.08 5.54 0.622
No 95.6 7.73 5.42a Data available for 723 patients.
The ASQoL scores were signiﬁcantly associated with but-
ock pain (p = 0.032), cervical pain (p < 0.001) and hip pain
p = 0.001) (Table 3). Clinical variables as inﬂammatory low back
ain, enthesitis, dactylitis, upper limb arthritis, lower limb
rthritis, uveitis, inﬂammatory bowel disease, psoriasis, and
rethritis did not inﬂuence the ASQoL score (Table 2).
Regarding treatment, patients who took NSAID continu-
usly presented higher ASQoL scores (p < 0.001). The other
edications, like corticosteroids, methotrexate, and sul-
asalazine did not inﬂuence the ASQoL scores. Biologic agents,
specially adalimumab, were associated with lower scores of
SQoL (p = 0.013) (Table 4).
iscussion
espite speciﬁc instruments to assess QoL cannot be easily
pplied to other diseases, ASQoL had a good performance
n the evaluation of this large series of patients with SpA.
lthough AS patients presented higher ASQoL scores, there
as no statistical signiﬁcance among the ASQoL scores in
he different diseases in the group; the mean ASQoL scoreASQoL, Ankylosing Spondylitis Quality of Life; IBD, inﬂammatory
bowel disease.
(7.74 ± 5.39) indicated that the analyzed patients had a signif-
icant low quality of life.
Patients with the mixed (axial + peripheral and/or enthe-
seal) articular presentation had higher ASQoL scores, as
expected. Interestingly, the entheseal involvement was associ-
ated with the highest ASQoL scores, indicating that enthesitis
can contribute to a signiﬁcant decrease in the QoL of the
affected patients.
While SpA is more  frequent in male Caucasian patients,
the ASQoL was worse in female African-Brazilian patients
in the present series. These data can conﬁrm that women
usually demonstrate greater dissatisfaction with the disease
than men. Some studies have analyzed the associated pres-
ence of ﬁbromyalgia and AS,12,13 a clinical situation that can
possibly confound the results related to QoL. Another study,
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Table 4 – ASQoL scores, according to treatment.
N (%) ASQoL score p
Mean SD
NSAID > 50%
Yes 35.2 8.65 5.22  <0.001
No 64.8 7.25 5.43
NSAID on demand
Yes 24.9 7.68 5.22 0.795
No 75.1 7.76 5.45
Corticosteroids
Yes 35.4 7.93 5.41 0.324
No 64.6 7.64 5.39
Methotrexate
Yes 51.7 7.90 5.32 0.252
No 48.3 7.57 5.47
Sulfasalazine
Yes 44.7 8.02 5.41 0.078
No 55.3 7.52 5.37
Inﬂiximab
Yes 15.3 7.20 5.49 0.105
No 84.7 7.84 5.37
Etanercept
Yes 2.8 9.44 5.82 0.065
No 97.2 7.69 5.37
Adalimumab
Yes 2.3 5.70 4.48 0.013
No 97.7 7.79 5.40
ASQoL, Ankylosing Spondylitis Quality of Life; NSAID, nonsteroidal
r
questionnaire. Clin Exp Rheumatol. 2010;28:379–85.anti-inﬂammatory drugs.
conducted in Brazil, evaluating 71 AS patients (45.5% males
and 54.5% females), observed that ﬁbromyalgia was more
prevalent among women (3.8:1) and may have inﬂuenced
the higher BASDAI, BASFI and ASQoL scores in the patients
with associated ﬁbromyalgia.14 Anxiety and depression can
also be involved in the impairment of QoL in AS patients.15
Fibromyalgia, as well as speciﬁc questionnaires for anxiety
and depression were not assessed in the present study.
The referred higher ASQoL scores observed in the African-
Brazilians, indicating a lower QoL, can be explained by the
genetic background and the inﬂuence of socio-economic fac-
tors, such as access to health services and access to speciﬁc
treatments. This aspect deserves further studies addressing
speciﬁcally the socio-economic proﬁle of our patients with
SpA.
The practice of exercise was associated with lower scores
of ASQoL, similar to that observed in a Turkish study analyzing
942 AS patients.16 A recent British study with 612 AS patients
showed that smoking has a dose-dependent relationship with
increased disease activity, decreased function, and poor qual-
ity of life, independent of age, gender, deprivation level, and
disease duration.17
In a group where a signiﬁcant number of patients present
axial and peripheral articular involvement, the ASQoL scores
were signiﬁcantly higher in those patients presenting buttock
pain, cervical pain and hip pain. This can reﬂect the fact that
the ASQoL was developed for patients with AS, a disease where 2 0 1 6;5 6(1):22–27
the axial component represents its core symptoms. It is also
important to mention that 18.8% of the studied patients had
PsA, a disease with predominant peripheral component and
that has a speciﬁc QoL instrument, the Psoriatic Arthritis Qual-
ity of Life (PsAQoL).18 However, considering that PsAQoL was
not translated and validated to the Brazilian Portuguese at the
time of the data collection, and the fact that 10 of the 18 ques-
tions of the ASQoL are quite similar to 10 of the 20 questions of
the PsAQoL, we understood that ASQoL could be used in that
heterogeneous group of SpA patients.
In general, the applicability of ASQoL uses to be very good.19
A recent study with 522 AS patients from Canada and Aus-
tralia showed that contextual factors, such as helplessness
and employment had an important and independent contri-
bution to health-related QoL, explaining 47% of the ASQoL
variance.20
The continuous use of NSAID was associated with higher
scores of ASQoL, while NSAID use on demand did not con-
tribute to an impairment of ASQoL. It can be associated to the
increased pain and functional limitation observed in patients
who generally have continuous use of NSAID, contributing to
a decreased quality of life in these patients. The use of biologic
agents was associated with better QoL, as shown in previous
studies.21,22
Concluding, this large Brazilian series of patients with SpA
showed that female gender and African-Brazilian ethnicity,
as well as the mixed (axial + peripheral) clinical presentation,
were associated with impaired quality of life.
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